These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 1729540)

  • 61. Life quality of patients with metastatic renal cell carcinoma and chemo-immunotherapy--a pilot study.
    Kröger MJ; Menzel T; Gschwend JE; Bergmann L
    Anticancer Res; 1999; 19(2C):1553-5. PubMed ID: 10365144
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Possible synergy of radiotherapy and chemo-immunotherapy in metastatic renal cell carcinoma (RCC).
    Brinkmann OA; Bruns F; Prott FJ; Hertle L
    Anticancer Res; 1999; 19(2C):1583-7. PubMed ID: 10365150
    [TBL] [Abstract][Full Text] [Related]  

  • 63. [The surgical opportunity in metastatic lesions of renal-cell carcinoma after a response to adjuvant immunotherapy].
    Olivier C; Carballido J; Lao AH; Bellido D; Ramón y Cajal S; Manzano L; Ondina L; Alvarez-Mon M
    Actas Urol Esp; 1995 Mar; 19(3):203-10. PubMed ID: 8659277
    [TBL] [Abstract][Full Text] [Related]  

  • 64. [Immunotherapy of renal cell carcinoma: results from current phase-III-trials].
    Doehn C; Jocham D
    Aktuelle Urol; 2004 Apr; 35(2):121-9. PubMed ID: 15146376
    [TBL] [Abstract][Full Text] [Related]  

  • 65. [Renal cell carcinoma metastatic to the base of tongue: a case report].
    Kyan A; Kato SN
    Hinyokika Kiyo; 2004 Nov; 50(11):791-3. PubMed ID: 15628540
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Immunotherapy of metastatic renal cell cancer.
    Fishman M; Seigne J
    Cancer Control; 2002; 9(4):293-304. PubMed ID: 12228755
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Preparative cytoreductive surgery in patients with metastatic renal cell carcinoma treated with adoptive immunotherapy with interleukin-2 or interleukin-2 plus lymphokine activated killer cells.
    Robertson CN; Linehan WM; Pass HI; Gomella LG; Haas GP; Berman A; Merino M; Rosenberg SA
    J Urol; 1990 Sep; 144(3):614-7; discussion 617-8. PubMed ID: 2201792
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Does radical nephrectomy with immunochemotherapy have any superiority over embolization alone in metastatic renal cell carcinoma? A preliminary report.
    Demirci D; Tatlişen A; Ekmekçioğlu O; Ozcan N; Kaya R
    Urol Int; 2004; 73(1):54-8. PubMed ID: 15263794
    [TBL] [Abstract][Full Text] [Related]  

  • 69. [Individualized therapy with alpha-interferon in metastatic renal cell carcinoma].
    Gross AJ; Dieckmann KP; Krain J; Huland H
    Urologe A; 1995 Mar; 34(2):158-61. PubMed ID: 7754588
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Renal cell cancer: is there long-term survival advantage from cytokine treatment?
    Oliver RT
    Eur J Cancer; 1994; 30A(9):1214-6. PubMed ID: 7999400
    [No Abstract]   [Full Text] [Related]  

  • 71. Is there a role for adjuvant immunochemotherapy after radical nephrectomy in pT2-3N0M0 renal cell carcinoma?
    Migliari R; Muscas G; Solinas A; Melis M; Ionta MT; Massidda B; Usai E
    J Chemother; 1995 Jun; 7(3):240-5. PubMed ID: 7562021
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Renal cell carcinoma with retroperitoneal lymph nodes: role of lymph node dissection.
    Pantuck AJ; Zisman A; Dorey F; Chao DH; Han KR; Said J; Gitlitz BJ; Figlin RA; Belldegrun AS
    J Urol; 2003 Jun; 169(6):2076-83. PubMed ID: 12771723
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Adjuvant 5-flurouracil, alpha-interferon and interleukin-2 versus observation in patients at high risk of recurrence after nephrectomy for renal cell carcinoma: results of a phase III randomised European Organisation for Research and Treatment of Cancer (Genito-Urinary Cancers Group)/National Cancer Research Institute trial.
    Aitchison M; Bray CA; Van Poppel H; Sylvester R; Graham J; Innes C; McMahon L; Vasey PA
    Eur J Cancer; 2014 Jan; 50(1):70-7. PubMed ID: 24074763
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Immunotherapy for renal cell carcinoma: the era of interleukin-2-based treatment.
    Taneja SS; Pierce W; Figlin R; Belldegrun A
    Urology; 1995 Jun; 45(6):911-24. PubMed ID: 7771023
    [No Abstract]   [Full Text] [Related]  

  • 75. Adjuvant immunotherapy in renal cell carcinoma--comparison of interferon alpha treatment with an untreated control.
    Basting R; Corvin S; Händel D; Hinke A; Schmidt D
    Anticancer Res; 1999; 19(2C):1545-8. PubMed ID: 10365142
    [TBL] [Abstract][Full Text] [Related]  

  • 76. A Phase I/Ib study of folate immune (EC90 vaccine administered with GPI-0100 adjuvant followed by EC17) with interferon-α and interleukin-2 in patients with renal cell carcinoma.
    Amato RJ; Shetty A; Lu Y; Ellis PR; Mohlere V; Carnahan N; Low PS
    J Immunother; 2014 May; 37(4):237-44. PubMed ID: 24714357
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Current clinical practice of induction and maintenance immunotherapy for metastatic renal cell carcinoma.
    Little B; Young M; Ho KJ
    Int J Clin Pract; 2002; 56(1):36-9. PubMed ID: 11831831
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Cytogenetic studies in renal cell carcinoma patients receiving low-dose recombinant interleukin-2-based immunotherapy.
    Duensing S; van den Berg-de Ruiter E; Störkel S; Kirchner H; Hänninen EL; Buer J; Poliwoda H; Atzpodien J
    Tumour Biol; 1996; 17(1):27-33. PubMed ID: 7501970
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Interferon-alpha/5-fluorouracil: a novel outpatient chemo/immunotherapy for progressive metastatic renal cell carcinoma.
    Lopez Hanninen E; Poliwoda H; Atzpodien J
    Cancer Biother; 1995; 10(1):21-4. PubMed ID: 7780483
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Immunotherapy for advanced renal cell cancer.
    Coppin C; Porzsolt F; Kumpf J; Coldman A; Wilt T
    Cochrane Database Syst Rev; 2000; (3):CD001425. PubMed ID: 10908496
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.